ArticleGenome medicine2025
MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology.
Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The seventh kidney cancer research summit: progress in accelerating cures.The oncologist · 2026Article
- A deep learning-based multimodal model with automated body composition analysis predicts prognosis in advanced clear cell renal cell carcinoma.Scientific reports · 2026Article
- Determinants of pancreatic tropism in metastatic renal cell carcinoma.JCI insight · 2026Article
- Artificial intelligence in digital pathology diagnosis and analysis: technologies, challenges, and future prospects.Military Medical Research · 2026Review
- Digital pathology and artificial intelligence in breast and gynecologic oncology: from molecular prediction to multimodal integration.Frontiers in oncology · 2026Review
- MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology.Genome medicine · 2025Article
- Gallbladder large cell neuroendocrine carcinoma in a patient with multiple myeloma: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTumor evolution, driven by the emergence of genetically and epigenetically distinct subclones, enables cancers to adapt to selective pressures and become more aggressive, posing a major challenge in oncology. Multi-regional sequencing has been the primary means of studying tumor evolution and the resultant intra-tumor heterogeneity (ITH), but its high cost, resource-intensiveness, and limited scalability have hindered clinical utility.
methodsHere, we present MorphoITH, a novel framework that aims to infer molecular ITH from routinely collected histopathology slides by quantifying phenotypic diversity. MorphoITH integrates a task-agnostic, self-supervised deep learning similarity measure to capture phenotypic variation across multiple dimensions (cytology, architecture, and microenvironment) along with rigorous methods to eliminate spurious sources of variation.
resultsApplying MorphoITH to clear cell renal cell carcinoma (ccRCC), a disease notably shaped by ITH, we show that it captures clinically significant biological features such as vascular architecture and nuclear grade. MorphoITH also recognizes morphological changes associated with subclonal alterations in key driver genes (BAP1, PBRM1, SETD2). Finally, in a multi-regional sequencing dataset, we find that the morphological trajectories revealed by MorphoITH largely mirror underlying patterns of genetic evolution.
conclusionsMorphoITH provides a scalable and rigorous approach to quantify morphological ITH, serving as a potential proxy for underlying genetic ITH and tumor evolution. By linking histopathology with genomic insights, it lays the foundation for more refined phenotypic profiling in support of precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.